Logista

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Logista

Quick Facts About Logista (Loratadine)

Property Description
Active ingredient Loratadine
Form Oral preparations (Tablet, Liquid, Capsule)
Pharmacological class Second-Generation Antihistamine
Common use Relief from symptoms of general allergic conditions
Origin Synthetic, Piperidine derivative

Defining the Drug Entity and Its Class

Logista is the commercial designation for a medicinal product containing the active ingredient Loratadine, which is classified as a second-generation antihistamine and a Histamine H1-receptor antagonist. This classification is clinically recognized for providing relief across diverse populations. This class of drug is widely used to manage symptoms related to allergic reactions.

Loratadine is a synthetic compound derived as a piperidine derivative. This structure is key to its therapeutic profile, as it possesses high selectivity for peripheral H1 receptors, which are located outside the central nervous system. This molecular feature is a differentiating factor from older antihistamines, allowing Logista to primarily target allergy response mechanisms without causing significant cognitive effects.

Composition, Form, and General Anti-Allergy Purpose

The medication is a single active ingredient product prepared for oral administration, and it is formulated as a long-acting agent, which means its action is sustained over a full day. It is commonly supplied in several dosage forms, including the tablet, liquid, and capsule, allowing flexibility for different patient groups.

The fundamental purpose of Logista is to reduce the symptoms caused by the body's overreaction to allergens by selective inhibition of those peripheral H1 receptors. By preventing histamine from binding, the medication interrupts the cascade of symptoms such as itching and swelling associated with conditions like allergic rhinitis (hay fever) and chronic urticaria. Loratadine is used to provide symptom relief for allergic rhinitis and chronic urticaria, and the medication is an established option for controlling these widespread allergic manifestations.

Regulatory References

  1. MedlinePlus Drug Information on Loratadine

What side effects are possible with Logista?

Possible Side Effects and Safety Information

The safety profile of Logista (Loratadine) is structured according to standardized regulatory categories based on clinical trials and post-marketing reports, defining which adverse reactions are considered common and which are very rare.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their observed frequency. In clinical trials involving adults and adolescents, the most common documented effects reported more often than placebo include somnolence (drowsiness), headache, increased appetite, and insomnia. For children aged 2 through 12, common reactions include headache, nervousness, and fatigue.

Reactions identified through widespread post-marketing surveillance are considered very rare. These are reported across various System-Organ Classes (SOCs), including the Immune system (hypersensitivity reactions such as angioedema and anaphylaxis), the Nervous system (convulsion or seizures), and Cardiac disorders (tachycardia and palpitation). Abnormal hepatic function is also documented as a very rare reaction.

Regulatory Safety Considerations

Official regulatory documents detail specific constraints related to the drug's safety. Logista is contraindicated in individuals with a known hypersensitivity to loratadine or its excipients. Safety information also advises caution for populations with severe hepatic or renal impairment, where a dosage modification may be determined as necessary.

The regulatory label states that Logista should be discontinued at least 48 hours prior to skin allergy tests to prevent interference with test results. Furthermore, due to excretion into breast milk, the use of Logista is officially not recommended while breast-feeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Logista (loratadine) is primarily associated with documented manifestations affecting the central nervous and cardiovascular systems. These clinical signs typically include somnolence, a pronounced headache, and a rapid heart rate (tachycardia). In pediatric cases, an overdose may also present with extrapyramidal signs. The most serious concern following ingestion of a large overdose is the potential for cardiovascular consequences, including the risk of arrhythmias and QT interval prolongation, which necessitates continuous monitoring.

Mandated Emergency Response

In all instances of suspected overdose, regulatory authorities mandate that individuals must seek immediate medical attention or contact a local Poison Control Center right away. Urgent medical help, including calling emergency services, is required if the person collapses, experiences a seizure, has trouble breathing, or cannot be awakened.

Treatment is strictly symptomatic and supportive, as there is no specific antidote known for loratadine overdose. Management procedures described in official labels may involve administering activated charcoal to limit absorption. Close clinical observation and cardiac monitoring via an electrocardiogram (ECG) are typically required following a high-dose ingestion.

Therapeutic Uses of Logista

What Logista Treats: Main Uses and Benefits

Logista (Loratadine) is commonly used to help with symptomatic management across primary domains of allergic conditions. In conditions where patients experience heightened physiological activity, Logista is commonly used to help with symptomatic management and ease the overall symptom burden that often interferes with daily functioning. This medication is generally considered relevant for easing symptoms related to inflammatory or irritative states.

The medication is relevant in conditions characterized by periods of heightened symptoms, specifically allergic rhinitis (seasonal and perennial) and Chronic Urticaria (hives) and acute allergic skin manifestations. It assists in addressing disruptive symptom clusters like frequent sneezing, runny nose, itching of the eyes and nose, and symptoms related to physical discomfort, such as skin itching with the appearance of welts. Applied during phases when symptoms become more noticeable, Logista contributes to improved comfort during symptomatic periods, helping patients cope more steadily with symptom fluctuations.

“Logista is generally considered relevant for providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Support for Allergic Symptoms Logista contributes to easing the overall symptom load associated with both respiratory and cutaneous allergic manifestations.

Regulatory References

  1. NIH MedlinePlus overview of Loratadine

Eligibility and Restrictions for Use

Logista (Loratadine) eligibility is strictly defined by regulatory authorities across age, physiological status, and underlying conditions. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the active substance, loratadine, or to any of the product's excipients.

Age-Related Eligibility

Age Group Regulatory Status
Adults & Adolescents (ge 12 years) Approved for use.
Children (2 to 12 years) Approved for use.
Children (Under 2 years) Not recommended; safety and efficacy are not established.

Conditional Restrictions and Exclusions

Use is contraindicated for women who are breastfeeding, as regulatory documents state the substance passes into breast milk. Additionally, the medicine is restricted in populations with severe hepatic impairment or severe renal impairment (GFR < 30 mL/min). Official labeling advises that these populations require conditional use, often involving an adjusted dosage schedule due to altered drug clearance. Certain formulations may also be restricted for patients with hereditary conditions like galactose intolerance. (160 words)

What should I know about interactions with other medicines?

The official regulatory profile for Logista (Loratadine) details specific pharmacokinetic interactions and mandatory administration constraints as documented by government health authorities. This information is classified to inform on potential changes to drug exposure or necessary timing separations.

Interaction Domain Officially Documented Finding
Pharmacokinetic Interactions Co-administration with inhibitors of the Cytochrome P450 (CYP) 3A4 and 2D6 enzyme systems—specifically Ketoconazole, Erythromycin, and Cimetidine—is formally documented to cause substantially increased plasma concentrations of Logista and its active metabolite. This outcome is a regulatory pharmacokinetic finding.
Procedural Timing Constraint Logista administration must be discontinued at least 48 hours prior to conducting skin tests for allergies. This mandatory separation is required because antihistamines can interfere with the necessary dermal reactivity for accurate test results.
Food and Substance Status Ingesting food is documented to delay the absorption of Logista, while also causing an increase in the drug’s overall systemic exposure (AUC). Regulatory data also confirms no potentiating effects when Logista is administered concomitantly with alcohol, based on controlled psychomotor performance studies.
Population-Specific Restriction Severe hepatic impairment is noted as a condition leading to reduced drug clearance, which constitutes an interaction-related administration restriction for this population due to the potential for altered systemic levels.

This structure emphasizes official findings regarding metabolic changes, procedural rules, and substance effects on clearance or absorption, strictly as defined in regulatory labeling.

Mechanism of Action

Selective Peripheral H1-Receptor Blockade

Logista's mechanism is driven by its active metabolite, Descarboethoxyloratadine, which functions as a selective inverse agonist at the peripheral Histamine H1-receptor. This targeted action is confined mainly to the body's periphery, restricting its effect to peripheral signaling pathways while resulting in minimal central H1-receptor occupancy.

Interruption of Histamine-Mediated Signaling

By stabilizing the H1-receptor in an inactive state, the drug's mechanism reduces the degree of activation of the signaling cascade normally mediated by histamine. This directly modulates the processes responsible for increased vascular permeability and sensory nerve stimulation, altering the dynamics of fluid extravasation and peripheral signal transmission.

Pharmacodynamic Selectivity and Action Profile

To ensure spatial selectivity, the drug and its active metabolite show poor ability to cross the blood-brain barrier (BBB), limiting the degree of central H1-receptor occupancy. The long half-life of the active metabolite allows for the maintenance of peripheral H1-receptor blockade for up to 24 hours.

Dosage and Administration Information

How to Use Logista (Loratadine)

Logista (loratadine) is administered exclusively via the oral route and is characterized by a once-daily dosing regimen. The long-acting nature of the compound is the basis for its use only once every 24 hours, and it may be taken without regard to mealtime. Available forms include 10 mg tablets, capsules, and oral solutions, providing flexibility for administration.

Standard Dosing Regimens

The standard prescribed dose for adults and adolescents who are 12 years of age and older is 10 mg once daily. This 10 mg amount is generally the maximum dose to be taken within a 24-hour period. For pediatric patients, the dose is determined by age and body weight. Children 6 years of age and older typically receive the standard 10 mg once daily dose. Children 2 to 5 years of age are administered a lower dose of 5 mg once daily.

Usage Adjustments and Specific Conditions

Specific dosage modifications are required for certain populations. Patients with severe hepatic (liver) impairment or severe renal (kidney) impairment (glomerular filtration rate <30 mL/min) typically follow a 10 mg dose on an every-other-day schedule. The medication is used during periods of acute or chronic symptoms. A specific procedural constraint involves allergy testing: the use of Logista is discontinued for at least 48 hours before a planned skin allergy test, as antihistamines can interfere with the test results.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Logista (Loratadine)

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research exploring Logista in relation to symptoms of allergic rhinitis largely consists of short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing Logista to either an inactive treatment (placebo) or to other studied interventions. Studies monitored outcomes related to physical discomfort, such as measurements of sneezing, runny nose, nasal itching, and itchy eyes, which were observed in the study populations. Findings describe symptom patterns observed in the studies, where patient-reported outcomes describing perceived discomfort were monitored over defined time intervals.

However, a key limitation in this area is that the follow-up durations were limited in most of the pivotal trials, often spanning only a few weeks. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes concerning symptom patterns over extended use.

Evidence for Use in Chronic Urticaria (Hives)

Research concerning chronic urticaria, or long-lasting hives, has mainly relied on Randomized Controlled Trials (RCTs). Logista was studied in relation to outcomes linked to inflammatory or irritative states, such as the appearance of skin lesions (wheals) and the intensity of pruritus (itching). Trials described that scores measuring urticaria activity, such as the Urticaria Activity Score (UAS), showed patterns of lower readings in the Logista groups compared to the placebo groups. The reported outcomes reflect the short-term changes observed in the appearance of skin lesions and associated discomfort.

Evidence Gaps and Areas of Uncertainty

Logista was evaluated in a variety of patient groups, including specific studies that examined its use in children alongside the primary research focused on adults and adolescents. Key limitations include that long-term symptom patterns are not fully established. Findings were mixed in some studies comparing Logista to certain other second-generation antihistamines, and the reliability of these specific comparisons remains limited. Data for certain groups, such as older adults with complex concurrent health issues, remain insufficient. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. NIH MedlinePlus: Loratadine

Frequently Asked Questions (FAQ)

Common questions about Logista (FAQ)


Q: How soon after starting Logista might someone expect to notice an effect?

Studies and official information indicate that the antihistaminic effects of Logista generally begin within one to three hours after taking the dose. The medicine reaches its maximum effect within approximately eight to twelve hours, maintaining its action for more than 24 hours. This profile is consistent with the drug’s long-acting classification.


Q: If I miss a dose of Logista, what is the generally advised procedure?

Official guidance states that if a dose is missed, it is generally advised to take the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, official guidance recommends skipping the missed dose entirely. Official patient information notes that taking more than one dose within a 24-hour period should be avoided.


Q: Are there official warnings about taking Logista during pregnancy?

Official regulatory documents indicate that Logista should be used during pregnancy only if the potential benefit justifies the possible risk to the fetus. While limited controlled data exists from human pregnancy studies, animal studies have generally not shown evidence of harm. Regulatory documents state that use during pregnancy requires consideration of the risks versus the benefits.


Q: Are there known interactions between Logista and common over-the-counter pain relievers?

Official drug interaction studies for Logista focus on specific enzyme inhibitors, such as Cimetidine and Ketoconazole. There are no specific warnings in official labeling for co-administration with most common single-ingredient pain relievers. Regulatory information advises checking the ingredients of combination cold and flu products, as they may contain similar active ingredients.


Q: Is Logista considered a controlled substance?

Regulatory documents confirm that Logista, which contains the active ingredient Loratadine, is not classified as a controlled substance in the United States or under similar international scheduling systems. The lack of controlled substance classification is noted in regulatory sources.


Q: Does Logista require a special type of prescription?

In many countries, Logista (loratadine) is available as an Over-The-Counter (OTC) medication and does not typically require a prescription. Specific formulations or country-specific regulations may require behind-the-counter dispensing, but it is generally an available product.


Q: What should I know if I need to stop taking Logista?

Official guidance mandates that Logista must be stopped at least 48 hours before any planned skin allergy testing to prevent interference with test results. For discontinuing the medication for reasons other than testing, it is guided by the healthcare professional.


Q: Why does the packaging for Logista have a specific black box warning?

According to official regulatory databases, Logista (loratadine) is not required to carry a specific FDA Boxed Warning. This type of severe warning is reserved for drugs carrying risks of serious or life-threatening adverse effects.


Q: Does Logista interact with birth control pills?

Official regulatory documentation for Logista has not identified or reported any clinically significant drug interactions concerning common hormonal contraceptives, such as birth control pills. No official warnings related to this co-administration are currently provided.


Q: What is the difference between Logista and a generic alternative?

Generic alternatives contain the identical active ingredient, loratadine, and must meet the same strict quality standards and demonstrate bioequivalence to the brand-name product. Differences are usually confined to the inactive ingredients, also called excipients, and the cost.


Q: Are there any warnings about driving or operating machinery while on Logista?

While Logista is generally known as a non-drowsy antihistamine, regulatory documents advise caution because very rare instances of drowsiness or reduced alertness can occur. Regulatory documents state that because reduced alertness can occur, activities such as driving or operating machinery should not be undertaken until the individual knows their personal response to the medication.


Q: Is it normal to feel nauseous when first taking Logista?

Regulatory documentation lists nausea as a very rare side effect of Logista. This classification means that it has been reported in less than 1 out of 10,000 people during clinical trials or through official post-marketing reports.


Q: What is the risk of overdose described in official documents for Logista?

Taking more of Logista than directed may lead to increased drowsiness. Official guidance states that immediate medical attention or contact with a Poison Control Center is required in the event of a suspected overdose.


Q: Does Logista have a risk of dependence or addiction?

Official regulatory documents do not classify Logista (loratadine) as a controlled substance, and official documentation does not indicate a risk of physical dependence or addiction associated with its use.


Q: Can Logista be taken alongside common cold and flu medications?

Loratadine, the active ingredient in Logista, is often combined with decongestants in official products. However, official guidance suggests patients avoid taking two separate products that contain the same or similar active ingredients. Regulatory sources generally advise checking for specific drug interactions with other cold and flu components.

How should Logista be stored and disposed of?

How to Store and Dispose of Logista?

Loratadine (Logista) requires specific conditions to maintain stability and safety, as documented in regulatory labeling.

  • Storage Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C and protect from freezing, especially the oral solution.

  • Protection and Container: Keep the medication in its original container and protect it from excessive moisture and light. It must be stored strictly out of the sight and reach of children.

  • Disposal Rules: Unused or expired Loratadine must be disposed of according to local requirements, such as national take-back programs. It must not be disposed of via wastewater or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Logista found in:

A-Z Index: